Methods for identifying and quantifying host cell proteins
Capillary electrophoresis with antibody immobilization effectively addresses the challenge of detecting and differentiating host cell proteins in biopharmaceuticals, enhancing purification processes and compliance with regulatory standards.
Patent Information
- Application Number
- JP2021569005
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-21
- Filing Date
- 2020-05-21
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-05-21
AI Technical Summary
Current methods for detecting and quantifying host cell proteins (HCPs) in biopharmaceutical preparations, such as monoclonal antibodies, are inadequate for selectively identifying and differentiating various species and impurities, particularly due to their complexity and the need for sensitive and specific assays to meet regulatory standards.
A capillary electrophoresis-based method that utilizes primary antibodies to immobilize and detect host cell protein contaminants by physical parameters like charge and molecular weight, enabling differentiation and quantification of these impurities.
The method allows for sensitive and selective detection and differentiation of HCPs, meeting regulatory requirements and providing insights into their impact on therapeutic antibody preparations, optimizing purification processes.
Smart Images

Figure 0007578619000001 
Figure 0007578619000002 
Figure 0007578619000003
Abstract
Description
[Technical field]
[0001] The present invention relates to biopharmaceuticals and to the use of capillary electrophoresis to detect contaminating polypeptides in biopharmaceutical preparations that contain host cell protein contaminants. [Background technology]
[0002] Monoclonal antibodies (mAbs) are an important class of biotherapeutic products and have achieved remarkable success in the treatment of many life-threatening and chronic diseases. However, mAbs are purified from a highly complex mixture of biological macromolecules with size and charge variants, various post-translational modifications including different glycosylation patterns, and N- and C-terminal heterogeneity. Thus, individual monoclonal antibody preparations may exhibit unique profiles of host cell proteins, characteristics that need to be considered in the evaluation of these products both during development and during the manufacture of the final product. For recombinant biopharmaceutical proteins to be acceptable for administration to human patients, it is critical that residual impurities resulting from the manufacturing and purification steps are removed from the final biological product. Components of these processes include culture media proteins, immunoglobulin affinity ligands, viruses, endotoxins, DNA, and host cell proteins. These host cell impurities include process-specific host cell proteins (HCPs), which are process-related impurities / contaminants in biologics derived from recombinant DNA technology. Although HCPs are typically present in small amounts (parts per million or nanograms per milligram of the intended recombinant protein) in the final drug substance, it is recognized that HCPs are undesirable and their amounts should be minimized. For example, the U.S. Food and Drug Administration (FDA) requires that biopharmaceuticals intended for in vivo application in humans be as free of impurities as possible and that tests for the detection and quantification of potential contaminants / impurities such as HCPs are required. In addition, the International Conference on Harmonization (ICH) provides guidelines on testing procedures and acceptance criteria for biotechnology / biological products. The guidelines suggest that for HCPs, highly sensitive immunoassays capable of detecting a wide range of protein impurities be utilized.
[0003] Sensitive analytical methods such as LC-MS / MS can be used to identify and quantify single HCP species present across protein components, requiring the development of alternative assays that are sensitive and specific enough to be validated for regulatory approval and can be used as a platform across multiple recombinant protein products.
[0004] Electrophoresis has been used to separate mixtures of molecules based on differences in their rates of migration in an electric field. In general, electrophoresis refers to the movement of suspended or dissolved molecules through a fluid or gel under the action of an electromotive force applied to one or more electrodes or conductive members in contact with the fluid or gel. Some known modes of electrophoretic separation include separating molecules based at least in part on differences in their mobility in a buffer solution (commonly referred to as zone electrophoresis), a gel or polymer solution (commonly referred to as gel electrophoresis), or the potential of a hydrogen (pH) gradient (commonly referred to as isoelectric focusing). Although capillary electrophoresis is effective for examining the purity and charge heterogeneity of biomolecules and is widely used in industry, it does not allow for selective detection of various species, nor does it allow for the differentiation of product and process impurities. Thus, additional methods of monitoring mAb preparations and formulations to detect host cell protein impurities are needed. Summary of the Invention
[0005] In one embodiment, the present invention provides a method for detecting a protein contaminant of interest in an antibody preparation sample, the method comprising separating protein components of the sample by physical parameters in one or more capillaries using capillary electrophoresis, immobilizing the protein components of the sample in said one or more capillaries, contacting said protein components in the one or more capillaries with one or more primary antibodies that specifically bind to the protein contaminant of interest, and detecting binding of the one or more primary antibodies, thereby detecting and quantifying the protein contaminant of interest in the antibody preparation sample.
[0006] In some embodiments, the method further comprises distinguishing variants of the protein contaminant of interest in the antibody preparation sample by a physical parameter.
[0007] In various embodiments of the methods, one or more of the capillaries comprises a separation matrix.
[0008] In various embodiments of the methods, the separation matrix comprises a carrier ampholyte.
[0009] In various embodiments of the method, the physical parameter comprises an electric charge.
[0010] In various embodiments of the methods, the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
[0011] In various embodiments of the method, the physical parameter comprises molecular weight.
[0012] In various embodiments of the methods, the one or more primary antibodies are labeled with a detectable label, and detecting binding of the one or more primary antibodies comprises detecting the detectable label.
[0013] In some embodiments, detecting binding of one or more primary antibodies comprises: contacting the one or more primary antibodies with a secondary antibody that specifically binds to at least one of the one or more primary antibodies, the secondary antibody bearing a detectable label; Detecting the detectable label. Includes.
[0014] In some embodiments, the method further comprises detecting and / or distinguishing charge or size variants of the protein contaminant of interest.
[0015] In some embodiments, the method further comprises determining the relative or absolute amount of the protein contaminant of interest.
[0016] In various embodiments of the methods, the detectable label comprises a chemiluminescent label, a fluorescent label, or a bioluminescent label.
[0017] In various embodiments of the methods, the sample includes an internal standard.
[0018] In some embodiments, immobilization comprises photoimmobilization, chemical immobilization, or thermal immobilization.
[0019] In various embodiments of the methods, the one or more primary antibodies comprise a polyclonal antibody.
[0020] In various embodiments of the methods, the one or more primary antibodies comprise a monoclonal antibody.
[0021] In various embodiments of the method, the protein contaminant of interest comprises PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or fragments thereof.
[0022] In another aspect, the present invention provides a method for detecting and / or differentiating a protein contaminant of interest in an antibody preparation sample by a physical parameter, the method comprising: separating protein components of the sample by a physical parameter in one or more capillaries using capillary electrophoresis; immobilizing the protein components of the sample in the one or more capillaries; contacting the protein components in the one or more capillaries with a first primary antibody that specifically binds to a first protein contaminant of interest; detecting binding of the first primary antibody, thereby detecting the first antibody of interest; contacting the protein components in the one or more capillaries with a second primary antibody that specifically binds to a second protein contaminant of interest; and detecting binding of the second primary antibody, thereby detecting the protein contaminant of interest to differentiate the protein contaminant of interest in the sample.
[0023] In some embodiments, the method further comprises contacting the protein component in the one or more capillaries with a third primary antibody that specifically binds to a third protein contaminant of interest and detecting binding of the third primary antibody, thereby detecting the third protein contaminant of interest.
[0024] In some embodiments, the method further comprises contacting the protein component in the one or more capillaries with one or more additional primary antibodies that specifically bind to one or more additional protein contaminants of interest and detecting binding of the one or more additional primary antibodies, thereby detecting the one or more additional protein contaminants of interest.
[0025] In some embodiments, the method further comprises distinguishing variants of the protein contaminant of interest in the antibody preparation sample by a physical parameter.
[0026] In various embodiments of the methods, one or more of the capillaries comprises a separation matrix.
[0027] In various embodiments of the methods, the separation matrix comprises a carrier ampholyte.
[0028] In various embodiments of the method, the physical parameter comprises an electric charge.
[0029] In various embodiments of the methods, the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
[0030] In various embodiments of the method, the physical parameter comprises molecular weight.
[0031] In various embodiments of the method, the primary antibody is labeled with a detectable label, and detecting binding of the primary antibody comprises detecting the detectable label.
[0032] In some embodiments, detecting binding of the primary antibody comprises: contacting the primary antibody with a secondary antibody that specifically binds to the primary antibody, the secondary antibody having a detectable label; Detecting the detectable label. Includes.
[0033] In some embodiments, the method further comprises determining the relative or absolute amount of one or more protein contaminants of interest.
[0034] In various embodiments of the methods, the detectable label comprises a chemiluminescent label, a fluorescent label, or a bioluminescent label.
[0035] In various embodiments of the methods, the sample includes an internal standard.
[0036] In various embodiments of the methods, the one or more primary antibodies comprise a polyclonal antibody.
[0037] In various embodiments of the methods, the one or more primary antibodies comprise a monoclonal antibody.
[0038] In various embodiments of the method, immobilization comprises photoimmobilization, chemical immobilization, or thermal immobilization.
[0039] In various embodiments of the method, the protein contaminant of interest comprises PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or fragments thereof.
[0040] In various embodiments, any of the features or components of the embodiments described above or discussed herein can be combined, and such combinations are encompassed within the scope of the present disclosure. Any particular value described above or discussed herein can be combined with another associated value described above or discussed herein to recite ranges having values representing the upper and lower ends of the range, and such ranges are encompassed within the scope of the present disclosure. [The present invention 1001] 1. A method for detecting a protein contaminant of interest in an antibody preparation sample, comprising: separating protein components of the sample according to physical parameters in one or more capillaries using capillary electrophoresis; immobilizing said protein components of said sample within said one or more capillaries; contacting the protein component in the one or more capillaries with one or more primary antibodies that specifically bind to a protein contaminant of interest; detecting said binding of said one or more primary antibodies, thereby detecting a protein contaminant of interest in the antibody preparation sample. A method comprising: [The present invention 1002] 1001. The method of claim 1001, further comprising differentiating variants of the protein contaminant of interest in the antibody preparation sample by said physical parameters. [The present invention 1003] The method of any one of claims 1001 to 1002, wherein said one or more capillaries comprises a separation matrix. [The present invention 1004] The method of any one of claims 10 to 3, wherein the separation matrix comprises a carrier ampholyte. [The present invention 1005] The method of claim 1004, wherein the physical parameter comprises an electric charge. [The present invention 1006] The method of any one of claims 10 to 13, wherein said separation matrix comprises a sieving matrix configured to separate proteins by molecular weight. [The present invention 1007] The method of claim 1006, wherein said physical parameters include molecular weight. [The present invention 1008] Any of the methods of claims 1001 to 1007, wherein the one or more primary antibodies are labeled with a detectable label, and detecting the binding of the one or more primary antibodies comprises detecting the detectable label. [The present invention 1009] detecting said binding of said one or more primary antibodies contacting the one or more primary antibodies with a secondary antibody that specifically binds to at least one of the one or more primary antibodies, the secondary antibody bearing a detectable label; detecting the detectable label; Any of the methods according to claims 1001 to 1008 of the present invention. [The present invention 1010] 1009. The method of any of claims 1001 to 1009, further comprising detecting and / or distinguishing charge variants or size variants of said protein of interest contaminant. [The present invention 1011] The method of any of claims 1001 to 1010, further comprising determining the relative or absolute amount of said protein contaminant of interest. [The present invention 1012] The method of any one of claims 1001 to 1011, wherein the detectable label comprises a chemiluminescent label, a fluorescent label, or a bioluminescent label. [The present invention 1013] The method of any one of claims 1001 to 1012, wherein the sample comprises an internal standard. [The present invention 1014] The method according to any one of claims 1001 to 1013, wherein said immobilizing comprises photoimmobilizing, chemical immobilizing, or thermal immobilizing. [The present invention 1015] The method of any of claims 1001 to 1014, wherein the one or more primary antibodies comprise a polyclonal antibody. [The present invention 1016] The method of any one of claims 1001 to 1015, wherein the protein contaminant of interest comprises PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or a fragment thereof. [The present invention 1017] 1. A method for detecting and / or differentiating a protein contaminant of interest in an antibody preparation sample by a physical parameter, comprising: separating protein components of the sample according to physical parameters in one or more capillaries using capillary electrophoresis; immobilizing protein components of the sample within the one or more capillaries; contacting the protein component in the one or more capillaries with a first primary antibody that specifically binds to a first protein contaminant of interest; detecting binding of the first primary antibody, thereby detecting the first antibody of interest; contacting the protein component in the one or more capillaries with a second primary antibody that specifically binds to a second protein contaminant of interest; detecting binding of the second primary antibody, thereby detecting the protein contaminant of interest, and differentiating between antibodies in the sample; A method comprising: [The present invention 1018] contacting the protein component in the one or more capillaries with a third primary antibody that specifically binds to the protein contaminant of interest; detecting binding of said third primary antibody, thereby detecting said third protein contaminant of interest; The method of the present invention 1017 further comprises: [The present invention 1019] contacting said protein components in said one or more capillaries with one or more additional primary antibodies that specifically bind to one or more additional protein contaminants of interest; detecting binding of said one or more additional primary antibodies, thereby detecting said additional protein contaminant of interest. The method of the present invention 1018 further comprises: [The present invention 1020] 1020. The method of any of claims 1017 to 1019, further comprising distinguishing variants of a protein contaminant of interest in an antibody preparation sample by said physical parameters. [The present invention 1021] The method of any one of claims 1017 to 1020, wherein said one or more capillaries comprises a separation matrix. [The present invention 1022] The method of claim 1021, wherein the separation matrix comprises a carrier ampholyte. [The present invention 1023] The method of claim 1022, wherein the physical parameter comprises an electric charge. [The present invention 1024] The method of claim 1021, wherein said separation matrix comprises a sieving matrix configured to separate proteins by molecular weight. [The present invention 1025] The method of claim 1024, wherein said physical parameters include molecular weight. [The present invention 1026] Any of the methods of claims 1017 to 1025, wherein the primary antibody is labeled with a detectable label, and detecting binding of the primary antibody comprises detecting the detectable label. [The present invention 1027] Detecting binding of the primary antibody, contacting the primary antibody with a secondary antibody that specifically binds to the primary antibody, the secondary antibody having a detectable label; detecting the detectable label; Any of the methods of 1017 to 1026 of the present invention, comprising: [The present invention 1028] 1027. The method of any of claims 1017 to 1027, further comprising determining the relative or absolute amount of said one or more protein contaminants of interest. [The present invention 1029] The method of any one of claims 1017 to 1028, wherein the detectable label comprises a chemiluminescent label, a fluorescent label, or a bioluminescent label. [The present invention 1030] The method of any one of claims 1017 to 1029, wherein the sample comprises an internal standard. [The present invention 1031] The method according to any one of claims 1017 to 1030, wherein said immobilizing comprises photoimmobilizing, chemical immobilizing, or thermal immobilizing. [The present invention 1032] The method of any one of claims 1017 to 1031, wherein the protein contaminant of interest comprises PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or a fragment thereof. [Brief description of the drawings]
[0041] [Figure 1] Figure 1A is a digital image of an SDS-PAGE and Western blot showing the formation of a preparation of the polypeptide PLBD2, and Figure 1B is a diagram showing the proposed form of PLBD2. [Diagram 2]Figure 2 is a set of digital images of Western blots with selected anti-PLBD2 antibody preparations. Mice were immunized with recombinant PLBD2 or HIC strips to generate anti-PLBD2 mAbs. Hybridomas were screened for specificity by Western blot and 10 were selected for purification and biotinylation. Mature PLBD2 protein (approximately 42 kDa) was not detected in any of the hybridomas. Antibodies targeting the N-terminus were identified. [Diagram 3] Figure 3 is a bar graph showing the activity of anti-PLBD2 antibodies. From these studies, mAb09 coating and biotinylated goat pAb assay was selected for the final sandwich ELISA format. [Figure 4] FIG. 4 is a schematic diagram of the sandwich ELISA using selected anti-PLBD2 antibodies. [Diagram 5] FIG. 5 is a standard curve generated for a selected pair of anti-PLBD2 antibodies. [Figure 6] FIG. 6 is an exemplary workflow for separation and detection of polypeptide contaminants by capillary electrophoresis using approximate molecular weights. [Figure 7] Figure 7 shows a series of graphs depicting the concentration-dependent analysis of PLBD2 under reducing and non-reducing conditions. The results show the quantification of PLBD2 in antibody samples. [Figure 8] FIG. 8 is a diagram of an exemplary workflow for separation and detection of polypeptides by charge-based capillary electrophoresis. [Figure 9] Figure 9 shows the results of an imaged cIEF-Western charge assay. PLBD2 is detected using an anti-PLBD2 pAb. PLBD2 is absent in C2P2 treated and inclusion samples confirmed that the CE-Western specifically picked up the PLBD2 peak in the 5-6 region. [Figure 10]Figure 10 shows the results of an imaged cIEF-Western (icIEF-Western) charging assay. Native PLBD2 can be seen in the pH region of 5-6 in the right diagram. It was detected from the mAb process, demonstrating the ability of this method to selectively detect PLBD2 from process samples. In this charging mode, specific polyclonal and monoclonal antibodies against PLBD2 can be used to detect impurities in the processed samples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0042] Before describing the present invention, it is to be understood that the present invention is not limited to a particular method, and the experimental conditions described, for example, methods and conditions, may vary. It is also to be understood that the terminology used herein is for the purpose of describing only particular embodiments, and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims. Any embodiment or features of the embodiments may be combined with each other, and such combinations are expressly encompassed within the scope of the present invention.
[0043] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.As used herein, the term "about" means that when used with reference to a specific recited value, the value may vary from the recited value by 1% or less.For example, as used herein, the expression "about 100" includes 99 and 101, and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0044] Although any methods and elements similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and elements are described herein. All patents, applications and non-patent publications mentioned herein are incorporated by reference in their entirety.
[0045] Abbreviations used herein mAb: Monoclonal antibody biAb: bispecific antibody CE: Capillary electrophoresis SDS: Sodium dodecyl sulfate icIEF: Imaged CIEF icIEF-Western; Charge-Based CE-Western IEC: Ion exchange chromatography QC: Quality control HRP: Horseradish peroxidase HCP: host cell protein
[0046] definition The term "antibody" as used herein is intended to mean an immunoglobulin molecule comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds (i.e., an "intact antibody molecule"), as well as multimers thereof (e.g., IgM) or antigen-binding fragments thereof, each heavy chain containing a heavy chain variable region ("HCVR" or "V H ") and the heavy chain constant region (C H 1. C H 2 and C H In various embodiments, the heavy chain may be of the IgG isotype. Optionally, the heavy chain is selected from IgG1, IgG2, IgG3 or IgG4. In some embodiments, the heavy chain is of isotype IgG1 or IgG4, and optionally includes a chimeric hinge region of isotype IgG1 / IgG2 or IgG4 / IgG2. Each light chain comprises a light chain variable region ("LCVR" or "VVR"). L ") and the light chain constant region (C L ) is included. V H and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). H and VL consists of three CDRs and four FRs, arranged from amino to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody" includes both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass. The term "antibody" includes antibody molecules prepared, expressed, produced or isolated by recombinant means, e.g., antibodies isolated from a host cell transfected to express the antibody. For reviews of antibody structure, see Lefranc et al., IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, 27(1) Dev. Comp. Immunol. 55-77 (2003); and M. Potter, Structural correlates of immunoglobulin diversity, 2(1) Surv. Immunol. Res. 27-42 (1983).
[0047] The term antibody also includes "bispecific antibodies," which include heterotetrameric immunoglobulins that can bind multiple epitopes. One half of a bispecific antibody contains one heavy chain, one light chain, and six CDRs and binds one antigen or epitope, and the other half binds a different antigen or epitope. In some cases, bispecific antibodies can bind the same antigen but different or non-overlapping epitopes. In some cases, both halves of a bispecific antibody have the same light chain while retaining the dual specificity. Bispecific antibodies are generally described in U.S. Patent Application Publication No. 2010 / 0331527 (December 30, 2010).
[0048] The term "antigen-binding portion" of an antibody (or "antibody fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment consisting of two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; and (v) a dAb fragment consisting of the VH domain (Ward et al. (1989) Nature 133:1311-1322). 241:544-546), (vi) separated CDRs, and (vii) scFv, which is composed of two domains of an Fv fragment, VL and VH, joined by a synthetic linker to form a single protein chain, in which the VL and VH domains pair to form a monovalent molecule. Other forms of single chain antibodies, such as diabodies, are also encompassed by the term "antibody" (see, e.g., Holliger et al. (1993) 90 PNAS USA 6444-6448; and Poljak et al. (1994) 2 Structure 1121-1123).
[0049] Furthermore, antibodies and antigen-binding fragments thereof can be obtained using standard recombinant DNA techniques commonly known in the art (see Sambrook et al., 1989).
[0050] The term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human mAbs of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), such as CDRs and especially CDR3. However, the term "human antibody" as used herein is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) are grafted onto human FR sequences. The term includes antibodies recombinantly produced in or in cells of a non-human mammal. The term is not intended to include antibodies isolated from or generated in a human subject.
[0051] The term "sample", as used herein, refers to a mixture of molecules comprising at least one polypeptide of interest, such as a monoclonal antibody, a bispecific antibody and / or one or more host cell protein (HCP) contaminants, that is manipulated according to the methods of the invention, including, for example, separation, analysis, extraction, enrichment or profiling.
[0052] The terms "analysis" or "analyzing", as used herein, are used interchangeably and refer to any of a variety of methods of separating, detecting, isolating, purifying, solubilizing, detecting and / or characterizing molecules of interest (e.g., polypeptides such as antibodies and HCP contaminants) in a biopharmaceutical preparation, such as an antibody preparation.
[0053] "Chromatography" as used herein refers to a method of separating a mixture, for example a mixture containing peptides, proteins, polypeptides and / or antibodies, for example monoclonal antibodies. It involves passing the mixture through a stationary phase, which allows the separation of a molecule of interest from other molecules in the mixture and the isolation of one or more molecules of interest. In the methods disclosed herein, chromatography refers to capillary electrophoresis, including size-based capillary electrophoresis and isoelectric focusing or charge-based capillary electrophoresis.
[0054] As used herein, "contacting" includes bringing together at least two substances in solution or solid phase, e.g., contacting a sample with an antibody, such as an antibody that specifically binds to a molecule of interest, such as an HCP contaminant.
[0055] The term "isolated" as used herein refers to a biological component (e.g., an antibody, such as a monoclonal antibody) that has been substantially separated, produced, or purified from other biological components, i.e., other chromosomal and extrachromosomal DNA and RNA, proteins, lipids, and metabolites, in the cells of an organism in which the component naturally occurs or is transgenically expressed, and thus "isolated" nucleic acids, peptides, proteins, lipids, and metabolites include nucleic acids, peptides, proteins, lipids, and metabolites that have been purified by standard or non-standard purification methods. The term also encompasses nucleic acids, peptides, proteins, lipids, and metabolites prepared by recombinant expression in a host cell, as well as chemically synthesized peptides, lipids, metabolites, and nucleic acids.
[0056] The terms "peptide", "protein" and "polypeptide" refer interchangeably to a polymer of amino acids and / or amino acid analogs linked by peptide bonds or peptide bond mimetics. The 20 naturally occurring amino acids and their one-letter and three-letter names are: Alanine A Ala, C Cysteine C Cys, Aspartic acid D Asp, Glutamic acid E Glu, Phenylalanine F Phe, Glycine G Gly, Histidine H His, Isoleucine I He, Lysine K Lys, Leucine L Leu, Methionine M Met, Asparagine N Asn, Proline P Pro, Glutamine Q Gln, Arginine R Arg, Serine S Ser, Threonine T Thr, Valine V Val, Tryptophan w Trp, Tyrosine Y Tyr. In one embodiment, the peptide is a portion of an antibody or a fragment thereof, such as any of the fragments or antibody chains listed above. In some embodiments, the peptide may be post-translationally modified. In another embodiment, the peptide is an HCP contaminant.
[0057] "Detection" and "detection" have their standard meanings and are intended to encompass detection, including the presence, absence, measurement, and / or characterization of a contaminating polypeptide, e.g., a protein of interest, such as an HCP.
[0058] As used herein, the terms "protein of interest" and / or "target protein of interest" refer to any protein to be separated and / or detected by the methods provided herein. Suitable proteins of interest include contaminating proteins in antibody preparations, such as HCPs.
[0059] As used herein, the terms "standard" and / or "internal standard" refer to a well-characterized substance of known quantity and / or identity (e.g., known molecular weight, electrophoretic mobility profile) that can be added to both the sample and the standard and molecules in the sample based on molecular weight or isoelectric point. Comparison of the standard then provides a quantitative or semi-quantitative measurement of the amount of analyte, such as a contaminating protein, e.g., HCP, present in the sample.
[0060] overview Characterization of contaminating host cell protein variants is important to identify possible impacts on purification of potential or realized therapeutic antibodies. In addition to characterization of mAbs, understanding the nature of protein contaminants is another important factor in the development of mAb therapeutics. For example, control of residual Protein A, HCPs, residual DNA and other possible culture or purification residues is typically part of the drug substance specifications. In addition, such control provides valuable information regarding process consistency and performance. Thus, disclosed herein are size and / or charge based detection methods of host cell proteins (HCPs), using antibodies, e.g., monoclonal or polyclonal antibodies, specific for HCPs that contaminate the protein of interest. The disclosed methods allow for detection and visualization of problematic HCPs and their various species in processed samples (see, e.g., Figures 1A and 1B, which show heterogeneity in the hamster protein PLBD2, a common contaminant in samples purified from CHO cells). As used herein, PLBD2 refers to a gene or gene product, e.g., the PLBL2 protein produced by the PLBD2 gene. Thus, PLBD2 can refer to a gene or gene product that is synonymous with PLBL2 protein. These methods can detect and indicate various species of a given HCP impurity at low ppm levels. Thus, aspects of the present disclosure include methods for detecting protein contaminants of interest in monoclonal antibody preparation samples. The ability to distinguish between more contaminating host cell proteins of interest or fragments thereof in biological samples is becoming increasingly important, as the activity of the proteins and / or fragments may have different effects on the activity of active agents such as therapeutic antibodies. Thus, there is a need for methods to characterize potential contaminants of potential therapeutic mAbs and mAb formulations. The methods disclosed herein meet these needs.
[0061] Disclosed herein are methods for detecting and / or differentiating variants of contaminating host cell proteins in biological samples, such as monoclonal antibody (mAb) preparations, by physical parameters, such as the molecular weight or isoelectric point of the contaminating host cell proteins. The disclosed methods can be used for QC assessment of antibody preparations. In embodiments of the methods, a sample containing a contaminating host cell protein or contaminating host cell proteins of interest is resolved or separated, for example, on one or more capillaries of a CE-system, by using capillary electrophoresis. In certain embodiments, the sample is resolved or separated by molecular weight. Resolution by molecular weight allows one to determine what fragments or species of contaminating host cell proteins are present in the sample. In certain embodiments, the sample is resolved or separated by charge, for example, by isoelectric focusing. Separation of contaminating host cell proteins by charge has the added advantage of being able to determine the homogeneity of the contaminating host cell proteins, e.g., changes in the surface charge of the contaminating host cell proteins that are not easily seen by separation by molecular weight. In certain embodiments, the sample is resolved or separated in a single capillary. In certain embodiments, a sample is resolved or separated in multiple capillaries, eg, in parallel.
[0062] Once the protein components are resolved or separated in the one or more capillaries, the protein components, e.g., contaminating host cell proteins of interest, are immobilized within the capillaries such that the relative position of the contaminating host cell proteins of interest in the one or more capillaries is maintained. In an embodiment, the contaminating host cell proteins of interest are detected by contacting the protein components in the one or more capillaries containing the contaminating host cell proteins of interest with one or more primary antibodies that specifically bind to the contaminating host cell proteins of interest or fragments thereof to detect the presence of the contaminating host cell proteins or fragments thereof. In an embodiment, the method includes detecting binding of the one or more primary antibodies, e.g., because their mobility within the capillary is impaired by immobilization of the contaminating host cell proteins or fragments thereof. Detection of binding of the primary antibodies allows for detection and / or differentiation of size variants and / or alteration variants of the contaminating host cell proteins of interest or fragments thereof in the sample, e.g., depending on whether the sample is separated by mass or charge, respectively, along the length of the capillary. With respect to separation by molecular weight, by way of example, finer fragments are expected to migrate within the capillary. In embodiments, the sample may contain multiple proteins, such as at least two, at least three, at least four, at least five or more contaminating host cell proteins or fragments thereof, each of which can be detected using a primary antibody that specifically binds to an individual contaminating host cell protein or fragment thereof of interest. In some embodiments, the method further comprises determining the relative or absolute amount of the variant of the contaminating host cell protein in the sample, for example, by measuring the peak height or area that corresponds to the amount of labeled primary antibody detected and thus how much of the contaminating host cell protein or fragment thereof is available to bind to the labeled primary antibody. In some embodiments, the contaminating host cell protein of interest comprises one or more of PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or fragments thereof.In some embodiments, the protein contaminant of interest comprises PLBD2. In some embodiments, the sample comprises one or more internal standards in the sample, such as a molecular weight standard ladder, an isoelectric point standard ladder, or a standard used as a baseline or benchmark for determining the amount of contaminating host cell proteins or fragments thereof. In some embodiments, the method comprises detection and / or differentiation of charge variants or size variants of the protein contaminant of interest. In some embodiments, the relative or absolute amount of the protein contaminant of interest can be determined. In various embodiments of the method, the one or more primary antibodies comprise a polyclonal antibody, and in various embodiments of the method, the one or more primary antibodies comprise a monoclonal antibody.
[0063] In embodiments, the method includes separating protein components of a sample having two or more size variants of a contaminating host cell protein of interest, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or even more, by molecular weight in one or more capillaries using capillary electrophoresis. An example of a flow is shown in FIG. 6. In embodiments, the method includes immobilizing the protein components of the sample in one or more capillaries. In embodiments, the method includes contacting the protein components in the one or more capillaries with a first primary antibody that specifically binds to a first monoclonal antibody of interest. In embodiments, the method includes detecting binding of the first primary antibody, thereby detecting the first monoclonal antibody of interest. In some embodiments, a molecular weight-based profile or fingerprint of the contaminating host cell protein can be created, for example, of the contaminating host cell protein alone, for comparison with a molecular weight-based profile or fingerprint of the contaminating host cell protein in the mixture. This comparison can then be used to determine whether the contaminating host cell protein of interest changes in the mixture, for example, over time or across a preparation. This can be done to optimize conditions for preparation, for example to minimize the effect or activity of contaminating host cell proteins that may be present in a preparation of a given therapeutic mAb. This profile or fingerprint comparison can be done for any or all of the contaminating host cell proteins of interest in the mixture. In an embodiment, the method includes contacting the protein components in one or more capillaries with a second primary antibody that specifically binds to the second monoclonal antibody of interest. In an embodiment, the method includes detecting binding of the second primary antibody, thereby detecting the second monoclonal antibody of interest and differentiating between contaminating host cell proteins in the sample. This can be continued for multiple different contaminating host cell proteins in the sample.For example, in embodiments, the method can include contacting the protein components in one or more capillaries with a third primary antibody that specifically binds to a third contaminating host cell protein of interest and detecting binding of the third primary antibody, thereby detecting the contaminating host cell protein of interest. In additional embodiments, the method can include contacting the protein components in one or more capillaries with one or more primary antibodies that specifically bind to one or more additional contaminating host cell proteins, e.g., a fourth, fifth, sixth, seventh, etc. primary antibody, and detecting binding of the one or more primary antibodies, thereby detecting the contaminating host cell protein of interest. In embodiments, the sample is split into multiple capillaries, each of which is contacted with a different primary antibody or primary antibodies and detected. The resulting signals can be later combined. In certain embodiments, detection can be performed in a single capillary, e.g., multiplexed.
[0064] In embodiments, the method includes separating protein components of a sample with two or more charge variants of a host cell protein of interest, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or even more contaminating host cell proteins, by charging in one or more capillaries using capillary electrophoresis, e.g., by isoelectric focusing. In embodiments, the method includes immobilizing protein components of a sample in one or more capillaries. An exemplary flow is shown in FIG. 8. In embodiments, the method includes contacting protein components in the one or more capillaries with a first primary antibody that specifically binds to a first monoclonal antibody of interest. In embodiments, the method includes detecting binding of the first primary antibody, thereby detecting the first monoclonal antibody of interest. In some embodiments, a charge-based profile or fingerprint of the contaminating host cell proteins can be generated of only the contaminating host cell proteins, e.g., for comparison to a charge-based profile or fingerprint of the contaminating host cell proteins in the mixture. This comparison can then be used to determine whether the contaminating host cell protein of interest changes in the mixture, e.g., over time or throughout the preparation. This can be done to optimize conditions for the preparation, e.g., to minimize the effect or activity of contaminating host cell proteins that may be present in a preparation of a given therapeutic mAb. This profile or fingerprint comparison can be done for any or all of the contaminating host cell proteins of interest in the mixture. In an embodiment, the method includes contacting the protein components in one or more capillaries with a second primary antibody that specifically binds to the second monoclonal antibody of interest. In an embodiment, the method includes detecting binding of the second primary antibody, thereby detecting the second monoclonal antibody of interest and differentiating between the contaminating host cell proteins in the sample. This can be continued for multiple different contaminating host cell proteins in the sample.For example, in an embodiment, the method can include contacting the protein components in one or more capillaries with a third primary antibody that specifically binds to a third contaminating host cell protein of interest and detecting binding of the third primary antibody, thereby detecting the contaminating host cell protein of interest. In a further embodiment, the method can include contacting the protein components in one or more capillaries with one or more primary antibodies that specifically bind to one or more additional contaminating host cell proteins, e.g., a fourth, fifth, sixth, seventh, etc. primary antibody, and detecting binding of the one or more primary antibodies, thereby detecting the contaminating host cell protein of interest. In an embodiment, the sample is split into multiple capillaries, each of which is contacted with a different primary antibody or primary antibodies and detected. The resulting signals can be later combined. In certain embodiments, detection can be performed in a single capillary, e.g., multiplexed.
[0065] Samples for use in the disclosed methods may be heterogeneous, containing various components, i.e., different proteins. Alternatively, the sample may be homogenous, containing one or essentially one component of multiple charge or molecular weight species. Pre-analytical processing may be performed on the sample before detecting the protein of interest, such as a contaminating protein. For example, the sample may be subjected to a lysis step, a denaturation step, a heating step, a purification step, a precipitation step, a immunoprecipitation step, a column chromatography step, a centrifugation step, etc. In some embodiments, separation and fixation of the sample may be performed on a natural substrate. In other embodiments, the sample may be subjected to denaturation, e.g., heat and / or contact with a denaturing agent. Denaturing agents are known in the art. In some embodiments, the sample may be subjected to non-reducing conditions. In some embodiments, the sample may be subjected to reducing conditions, e.g., contact with one or more reducing agents. Reducing agents are known in the art.
[0066] In some embodiments, the primary antibody is labeled with a detectable label, and detecting binding of the one or more primary antibodies comprises detecting the detectable label. In some embodiments, detecting binding of the one or more primary antibodies comprises contacting the one or more primary antibodies with a secondary antibody that specifically binds to at least one of the one or more primary antibodies, and detecting binding of the secondary antibody. In embodiments, the secondary antibody has a detectable label, and the detectable label is detected.
[0067] In some embodiments, the primary antibody and / or the secondary antibody comprises one or more detectable labels. In some embodiments, the detectable label comprises a chemiluminescent label, a fluorescent label, or a bioluminescent label. In some embodiments, the detectable label comprises a chemiluminescent label. A chemiluminescent label can comprise any entity that provides a light signal and can be used according to the methods disclosed herein. A variety of such chemiluminescent labels are known in the art, see, for example, U.S. Patent Nos. 6,689,576, 6,395,503, 6,087,188, 6,287,767, 6,165,800, and 6,126,870. Suitable labels include enzymes that can react with a chemiluminescent substrate in such a way that chemiluminescent photon emission is induced. Such enzymes induce chemiluminescence of other molecules through enzymatic activity. Such enzymes can include peroxidases such as horseradish peroxidase (HRP), beta-galactosidase, phosphatases, or others for which chemiluminescent substrates are available. In some embodiments, the chemiluminescent label can be selected from any of the various classes of luminol labels, isoluminol labels, and the like. In some embodiments, the primary antibody comprises a chemiluminescent labeled antibody. Chemiluminescent substrates are well known in the art, such as, for example, galactone substrates available from Applied Biosystems, Foster City, Calif., or SuperSignal West Femto Maximum Sensitivity substrates available from Pierce Biotechnology, Inc., Rockford, Ill., or other suitable substrates.
[0068] In some embodiments, the detectable label comprises a bioluminescent compound. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of the bioluminescent compound is determined by detecting the presence of luminescence. Suitable bioluminescent compounds include, but are not limited to, luciferin, luciferase and aequorin.
[0069] In some embodiments, the detectable label comprises a fluorescent label, such as a fluorescent dye. A fluorescent dye can include any entity that provides a fluorescent signal and can be used in accordance with the methods and apparatus described herein. Typically, a fluorescent dye comprises a resonant delocalized or aromatic ring system that absorbs light at a first wavelength and emits fluorescence at a second wavelength in response to an absorption event. A wide variety of such fluorescent dye molecules are known in the art. For example, the fluorescent dye can be selected from any of a variety of classes of fluorescent compounds, non-limiting examples of which include xanthenes, rhodamines, fluoresceins, cyanines, phthalocyanines, squaraines, body dyes, coumarins, oxazines, and carbopyronines. In some embodiments, for example, when the primary and / or secondary antibodies contain fluorophores, such as fluorescent dyes, their fluorescence is detected by exciting them with an appropriate light source and monitoring their fluorescence with a detector sensitive to their characteristic fluorescence emission wavelengths. In some embodiments, the primary antibody comprises a fluorescent dye-labeled antibody.
[0070] In embodiments, two or more different primary or secondary antibodies that bind to or interact with different proteins of interest, such as different contaminating proteins of interest, can be used to simultaneously detect different types of proteins of interest, e.g., in multiplex in the same or a single capillary, e.g., using different or even the same detectable labels. In some embodiments, multiple primary and / or secondary antibodies can be used with multiple substrates to provide color multiplexing. For example, the different chemiluminescent substrates used will be selected such that they emit photons of different colors. Selective detection of different colors can be achieved by using a diffraction grating, a prism, a series of colored filters, or other means.
[0071] In embodiments, the capillaries can include a separation matrix, which can be added in an automated manner by the device and / or system. In some embodiments, the sample is loaded onto the stacker matrix prior to separation. The separation matrix, in one embodiment, is a size separation matrix, which has similar or substantially the same properties of polymer gels used in conventional electrophoretic techniques. Capillary electrophoresis in a separation matrix is similar to separation in a polymer gel, such as a polyacrylamide gel or an agarose gel, where molecules are separated based on the size of the molecules in the sample, providing a porous passageway through which the molecules can move. The separation matrix allows for the separation of molecules by molecular size, since larger molecules move through the matrix more slowly than smaller molecules. In some embodiments, one or more capillaries include a separation matrix. In some embodiments, a sample containing a protein of interest is separated or divided based on molecular weight. In some embodiments, the separation matrix includes a sieving matrix configured to separate proteins by molecular weight. In some embodiments, the protein components of the sample are separated by molecular weight, and the method is a method of detecting and / or distinguishing size variants of a monoclonal antibody of interest. In some embodiments, the protein components of the sample are separated by molecular weight and the method is a method for detecting and / or distinguishing size variants of a contaminating protein of interest.
[0072] A wide variety of solid phase substrates, e.g., gels, such as polyacrylamide gels, are known in the art. In some embodiments, separating one or more proteins of interest comprises electrophoresis of a sample in a polymer gel. Electrophoresis in a polymer gel, such as a polyacrylamide gel or an agarose gel, separates molecules based on their size. The polymer gel provides a porous passageway through which the molecules can move. Larger molecules move through the gel more slowly than smaller molecules, allowing the separation of molecules by molecular size.
[0073] In some embodiments, a sample containing a protein of interest is separated or resolved based on the charge of the components of the sample. In some embodiments, the protein components of the sample are separated by charge and the method is a method of detecting and / or distinguishing charge variants of a monoclonal antibody of interest. In some embodiments, the protein components of the sample are separated by charge and the method is a method of detecting and / or distinguishing charge variants of a contaminating protein of interest. In some embodiments, the separation matrix comprises a carrier ampholyte. In some embodiments, separating the sample by charge comprises isoelectric focusing (IEF) of the sample. For example, in an electric field, a molecule migrates toward a pole (cathode or anode) that carries an opposite charge to the net charge carried by the molecule. This net charge depends in part on the pH of the medium through which the molecule migrates. One common electrophoretic method is to establish solutions with different pH values at each end of the electric field, with a gradient temperature range of pH between them. At one pH, the isoelectric point of the molecule is obtained and the molecule has no net charge. As a molecule traverses the pH gradient, it reaches a spot where it has zero net charge (i.e., its isoelectric point) and is then immobilized in an electric field. Thus, this method of electrophoresis separates molecules according to their different isoelectric points.
[0074] In some embodiments, for example when separation is by isoelectric focusing, an ampholyte reagent can be loaded into one or more capillaries of a capillary electrophoresis apparatus. The ampholyte reagent is a mixture of molecules having a range of different isoelectric points. Exemplary ampholyte reagents are Pharmalyte™ and Ampholine™ available from Amersham Biosciences, Buckinghamshire, England.
[0075] In embodiments, once separation is complete, the separated components of the sample (including, for example, the protein of interest, such as the contaminating protein of interest) are immobilized on the walls of one or more capillaries using any suitable method, including, but not limited to, chemical, photochemical, and heat treatment. In some embodiments, the separated components of the sample are immobilized in one or more capillaries of the CE-system after the molecules have been electrophoretically separated, for example, by size or charge. In some embodiments, immobilization includes photoimmobilization, chemical immobilization, or heat immobilization. Immobilization can be via covalent bonds or non-covalent means, such as by hydrophobic or ionic interactions. In certain embodiments, the protein of interest is immobilized using one or more reactive moieties. The reactive moieties can include any reactive group capable of forming a covalent bond with a corresponding reactive group of an individual molecule of the sample. Thus, the reactive moieties can include any reactive group known in the art, so long as they are compatible with the methods disclosed herein. In some embodiments, the reactive moieties include a reactive group capable of forming a covalent bond with a corresponding reactive group of said protein, such as the contaminating protein of interest.
[0076] The reactive moiety can be directly or indirectly attached to the capillary. In some embodiments, the reactive moiety can be provided in solution or suspension and, upon activation, can form a crosslink between the wall of the capillary and the molecules in the sample. For example, in one embodiment, immobilization occurs by exposing the separated sample and the capillary to ultraviolet (UV) light, which serves to immobilize the protein of interest (if present in the sample) and the molecules in the sample to the wall of the capillary. Immobilization can be via covalent bonds or non-covalent means, such as by hydrophobic or ionic interactions. In another embodiment, the reactive moiety can be used to covalently immobilize the separated protein of interest or the protein of interest in the capillary. The reactive moiety can be directly or indirectly attached to the capillary (e.g., the wall of the capillary). In some embodiments, the reactive moiety can be provided in solution or suspension and, upon activation, can be configured to form a crosslink between the wall of the capillary and the molecules in the sample. The reactive moieties can line the capillary or can be present on linear or crosslinked macromolecules in the capillary that may or may not be attached to the walls of the capillary before and / or after activation. The reactive moieties can be and / or include any reactive group, such as those described above, that can form a covalent bond with a corresponding reactive group on an individual molecule of the sample.
[0077] In some embodiments, the reactive moiety comprises a functional group that can be converted to a functionality that attaches to the protein of interest via hydrophobic interactions, ionic interactions, hydrogen bonding, etc. In some embodiments, the reactive moiety is activated with UV light, laser, temperature, or any other energy source to immobilize the protein of interest on the surface of the capillary and / or on the surface of a particle attached to the surface of the capillary. In some embodiments, the surface of the capillary is functionalized with a thermoresponsive polymer that allows for a change in the hydrophobicity of the surface upon changing the temperature. In some embodiments, the protein of interest is immobilized on such a surface by increasing the hydrophobicity of the temperature-responsive polymer when a certain temperature range is reached within the capillary.
[0078] A wide variety of reactive moieties suitable for covalently linking two molecules together are known in the art. For example, reactive moieties can be attached to carbon-hydrogen (CH) bonds of proteins. Since many separation media also contain components with CH bonds, chemical reactions that react with sulfhydryl (SH) groups can be advantageous in that SH groups are uniquely found on proteins compared to most separation media components. Suitable reactive moieties include, but are not limited to, photoreactive groups, chemically reactive groups, and thermally reactive groups. Photoimmobilization in capillary systems can be achieved by activation of one or more photoreactive groups. Photoreactive groups include one or more latent photoreactive groups that form covalent bonds with other molecules upon activation by an external energy source. See, for example, U.S. Patent Nos. 5,002,582 and 6,254,634. Photoreactive groups generate active species such as free radicals, particularly excited states of nitrenes, carbenes, and ketones, upon absorption of electromagnetic energy. The photoreactive group can be selected to respond to various parts of the electromagnetic spectrum, such as those that respond to ultraviolet, infrared and visible parts of the spectrum. For example, when exposed to a light source, the photoreactive group can be activated to form a covalent bond with an adjacent molecule. Suitable photoreactive groups include, but are not limited to, aryl ketones, azides, diazos, diazirines, and quinones. In some embodiments, the separated proteins of interest of the sample are immobilized in the capillary of the CE-system by isoelectric focusing.
[0079] Detectable label can be detected by any method known in the art, as long as it is compatible with the method described herein.Label detection can be performed by monitoring the signal using conventional methods and instruments, non-limiting examples include photodetectors, photodetector arrays, charge-coupled device (CCD) arrays, etc.Typically, detecting detectable label includes imaging the capillary.In some embodiments, the entire length of the capillary can be imaged.Alternatively, separate parts or portions of the capillary can be imaged.
[0080] The order of steps of the methods described herein may be changed as easily as would occur to one skilled in the art. For example, the sample may be separated and then the proteins of interest immobilized at their separated positions in the capillary may be separated before contacting the proteins of interest with the primary antibody. In some embodiments, the primary antibody may be contacted with the proteins of interest to form complexes, and then the complexes are separated in the capillary of the CE-system. In some embodiments, the primary antibody may be preloaded into the sample and then loaded into the system. As another example, a separation step such as isoelectric focusing may be applied after the chemiluminescent reagent is provided.
[0081] In some embodiments, the sample includes an internal standard. The internal standard serves to calibrate the separation with respect to isoelectric point or molecular weight. Internal standards for IEF are well known in the art, see, for example, K., Kamiya, K., Matsumoto, H., and K. Kasai (2002) Fluorescence-Labeled Peptide pI Markers for Capillary Isoelectric Focusing, Analytical Chemistry v74:1046-1053, and U.S. Pat. No. 5,866,683. Standards detected by fluorescence can be illuminated either before or after chemiluminescence, but generally cannot be illuminated simultaneously with chemiluminescence. In some embodiments, the protein of interest and the standard are detected by fluorescence. The protein of interest and the standard can each be labeled with a fluorescent dye that is detectable at an individual emission wavelength, so that the protein of interest and the standard are independently detectable.
[0082] In some embodiments, the internal standard may be a purified form of the protein of interest itself, generally rendered distinguishable in some way from the protein of interest. Methods of obtaining a purified form of the protein of interest may include, but are not limited to, purification from nature, purification from laboratory grown organisms (e.g., via chemical synthesis), and / or analogues. The distinguishing property of the internal standard may be, but is not limited to, dye labeling, radioactive labeling, or any suitable alteration that can modify the mobility of the standard during electrophoretic separation so that it is separated from the protein of interest. For example, the standard may include a modification of the protein of interest that changes the charge, mass, and / or length of the standard relative to the protein of interest (e.g., via deletion, fusion, and / or chemical modification). Thus, the protein of interest and the internal standard may each be labeled with a fluorescent dye that is detectable at a distinct emission wavelength, thereby rendering the protein of interest and the standard independently detectable. In some cases, the internal standard is different from the protein of interest, but behaves similarly or identically to the protein of interest, allowing for relevant comparative measurements. In some embodiments, standards suitable for use may be any of those described in U.S. Patent Application Publication No. 2007 / 0062813, the disclosure of which is incorporated herein by reference in its entirety.
[0083] As will be appreciated by those skilled in the art, virtually any method of loading a sample into a capillary can be implemented. For example, the sample can be loaded into one end of the capillary. In some embodiments, the sample is loaded into one end of the capillary by hydrodynamic flow. For example, in an embodiment where the fluid path is a capillary, the sample can be loaded into one end of the capillary by hydrodynamic flow, such that the capillary is used as a micropipette. In some embodiments, the sample can be loaded into the capillary by electrophoresis, for example, when the capillary is gel-filled and therefore more resistant to hydrodynamic flow.
[0084] A capillary can include any structure that allows liquids or dissolved molecules to flow. Thus, a capillary can include any structure known in the art as long as it is compatible with the method. In some embodiments, a capillary is a hole or channel through which liquids or dissolved molecules can flow. In some embodiments, a capillary is a passage in a permeable material through which liquids or dissolved molecules can flow.
[0085] The capillary comprises any material that allows for detection of the protein of interest within the capillary. The capillary comprises any convenient material, such as glass, plastic, silicon, fused silica, gel, etc. In some embodiments, the method uses multiple capillaries. Multiple capillaries allow for multiple samples to be analyzed simultaneously.
[0086] Capillaries can vary in size, width, depth and cross-section, as well as shape, such as round, trapezoidal, rectangular, etc. Capillaries can be straight, rounded, serpentine, or the like. As described below, the length of the fluid path depends in part on factors such as sample size and the degree of sample separation required to resolve proteins of interest.
[0087] In some embodiments, the capillary comprises a tube having a bore. In some embodiments, the method employs a plurality of capillaries. Suitable sizes include, but are not limited to, capillaries having an inner diameter of about 10 to about 1000 μm, however, capillaries having an inner diameter of about 25 to about 400 μm may be more commonly employed. Smaller diameter capillaries may employ relatively low sample loading, while the use of relatively large bore capillaries may allow relatively high sample loading, resulting in improved signal detection.
[0088] The capillaries can have a variety of lengths. Suitable lengths include, but are not limited to, capillaries that are about 2-20 cm in length, however, somewhat shorter and longer capillaries can be used. In some embodiments, the capillaries are about 3, 4, 5, or 6 cm in length. Longer capillaries typically result in better separation and improved resolution of complex mixtures. Longer capillaries can be particularly used to resolve low abundant proteins of interest.
[0089] Typically, the capillaries are constructed of fused silica, although plastic capillaries and Pyrex (i.e., amorphous glass) can be utilized. As noted above, the capillaries need not have a circular or tubular shape. Other shapes can be used as long as they are compatible with the methods described herein.
[0090] In some embodiments, the capillary can be a channel. In some embodiments, the method uses multiple channels. In some embodiments, the capillary can be a channel in a microfluidic device. Microfluidics uses channels in a substrate to perform a wide variety of operations. A microfluidic device can include one or more channels contoured into the surface of a substrate. A microfluidic device can be obtained from a solid inert substrate, and in some embodiments, in the form of a chip. The dimensions of the microfluidic device are not critical, but in some embodiments, the dimensions are on the order of about 100 μm to about 5 mm thick and about 1 centimeter to about 20 centimeters side. Suitable sizes include, but are not limited to, channels having a depth of about 5 μm to about 200 μm, although more typically, channels having a depth of about 20 μm to about 50 μm can be utilized. Smaller channels, such as microchannels or nanochannels, can also be used as long as they are compatible with the method.
[0091] Although certain embodiments have been described in detail above, the description is merely illustrative. Therefore, it should be understood that many of the above aspects are not intended as necessary or essential elements unless expressly stated otherwise. Modifications of components or functions corresponding to and equivalent to the disclosed aspects of the exemplary embodiments, in addition to those described above, can be made by those skilled in the art having the benefit of this disclosure without departing from the spirit and scope of the embodiments defined in the following claims, and the scope is to be given the broadest interpretation so as to include such modifications and equivalent structures.
[0092] The following examples are provided to illustrate certain features of certain embodiments. However, the specific features described below should not be construed as limitations on the scope of the invention, but rather as examples whose equivalents will be recognized by those skilled in the art. EXAMPLES
[0093] Example 1 Antibody development for HCPs for CE-Western Goats and mice were immunized with recombinant PLBD2 or HIC strips to generate anti-PLBD2 pAbs and mAbs, respectively. Hybridomas were screened for specificity by Western blot and 10 were selected for purification and biotinylation. Mature PLBD2 protein (~42 kDa) was not detected in any of the hybridomas. Antibodies targeting the N-terminus were identified. Figure 2 is a set of digital images of Western blots with selected anti-PLBD2 antibody preparations. Figure 3 is a bar graph showing measured PLBD2 levels in antibody preparation samples with different combinations of anti-PLBD2 antibodies. ELISA measurements are compared with LC-MS data. From these studies, mAb09 coating and biotinylated goat pAb detection were selected for the final sandwich ELISA format. Figure 4 is a schematic of the sandwich ELISA with selected anti-PLBD2 antibodies. Figure 5 is a standard curve generated for selected anti-PLBD2 antibodies using the ELISA method.
[0094] Example 2 Size-based CE-Western separation and detection Antibody preparations containing the contaminant PLBD2 were analyzed by size-based CE-Western under reducing and non-reducing conditions (see Figure 7). The graph shows the concentration-dependent analysis of PLBD2, demonstrating that size-based CE-Western is comparable to ELISA measurements for the detection and quantification of mAb preparation contaminants. Furthermore, unlike ELISA, contaminating proteins are separated by molecular weight, allowing the determination of individual species contributing to the overall contamination.
[0095] Example 3 Charge-based CE-Western separation and detection Antibody preparations containing contaminant PLBD2 were analyzed by charge-based CE-Western (see Figures 9 and 10). Figure 9 shows the results of an imaged cIEF-Western (icIEF) charge assay. PLBD2 is detected using an anti-PLBD2 pAb. PLBD2 is absent in the C2P2 process and the inclusion of the sample confirmed that the CE-Western specifically picked up the PLBD2 peak in the 5-6 region. Figure 10 shows the results of an imaged cIEF-Western (icIEF) charge assay. Native PLBD2 can be seen in the pH 5-6 range in the right diagram. This was detected from the mAb treatment demonstrating the ability of this method to selectively detect PLBD2 from the treated sample. In this charge mode, the treated sample can be detected using a specific monoclonal antibody against PLBD2.
[0096] The present invention is not limited to the specific embodiments described herein. Indeed, various modifications of the present invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to be within the scope of the appended claims.
Claims
1. 1. A method for detecting two or more variants of at least one host cell protein contaminant of interest in an antibody preparation sample, comprising: separating protein components of the sample by physical parameters including one of isoelectric point, charge, size, molecular weight, or a combination thereof in one or more capillaries using capillary electrophoresis; immobilizing said protein components of said sample within said one or more capillaries; contacting said protein component in said one or more capillaries with one or more primary antibodies that specifically bind to a variant of at least one host cell protein contaminant of interest; detecting said binding of said one or more primary antibodies, thereby detecting a variant of at least one host cell protein contaminant of interest in the antibody preparation sample; A method comprising:
2. 10. The method of claim 1, further comprising distinguishing between two or more variants of at least one host cell protein contaminant of interest in an antibody preparation sample by said physical parameter.
3. The method of claim 1 or 2, wherein the one or more capillaries comprise a separation matrix.
4. The method of claim 3 , wherein the separation matrix comprises a carrier ampholyte.
5. The method of claim 4 , wherein the physical parameter comprises an electric charge.
6. The method of claim 3 , wherein the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
7. The method of claim 6 , wherein the physical parameter comprises molecular weight.
8. 8. The method of any one of claims 1 to 7, wherein the one or more primary antibodies are labeled with a detectable label, and detecting the binding of the one or more primary antibodies comprises detecting the detectable label.
9. detecting said binding of said one or more primary antibodies contacting the one or more primary antibodies with a secondary antibody that specifically binds to at least one of the one or more primary antibodies, the secondary antibody bearing a detectable label; detecting the detectable label; The method according to any one of claims 1 to 8, comprising:
10. The method of any one of claims 1 to 9, further comprising detecting and / or differentiating charge variants or size variants of said at least one host cell protein contaminant of interest.
11. The method of any one of claims 1 to 10, further comprising determining the relative or absolute amount of said variant of at least one host cell protein contaminant of interest.
12. The method of any one of claims 1 to 11, wherein the detectable label comprises a chemiluminescent label, a fluorescent label or a bioluminescent label.
13. The method of any one of claims 1 to 12, wherein the sample comprises an internal standard.
14. The method of any one of claims 1 to 13, wherein the immobilizing comprises photoimmobilizing, chemically immobilizing, or thermally immobilizing.
15. The method of any one of claims 1 to 14, wherein the one or more primary antibodies comprise a polyclonal antibody.
16. 16. The method of any one of claims 1 to 15, wherein the two or more mutants of at least one host cell protein contaminant of interest comprise PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or fragments thereof.
17. 1. A method for detecting and / or distinguishing two or more variants of a host cell protein contaminant of interest in an antibody preparation sample by physical parameters, comprising: separating protein components of the sample according to physical parameters in one or more capillaries using capillary electrophoresis; immobilizing protein components of the sample within the one or more capillaries; contacting the protein component in the one or more capillaries with a first primary antibody that specifically binds to a first variant of a host cell protein contaminant of interest; detecting binding of the first primary antibody, thereby detecting the first antibody of interest; contacting the protein component in the one or more capillaries with a second primary antibody that specifically binds to a second variant of the host cell protein contaminant of interest; detecting binding of the second primary antibody, thereby detecting variants of the host cell protein contaminant of interest, to differentiate between antibodies in the sample; A method comprising:
18. contacting the protein component in the one or more capillaries with a third primary antibody that specifically binds to a mutant of the host cell protein contaminant of interest; detecting binding of the third primary antibody, thereby detecting a third variant of the host cell protein contaminant of interest.
20. The method of claim 17, further comprising:
19. contacting said protein component in said one or more capillaries with one or more additional primary antibodies that specifically bind to one or more additional variants of the host cell protein contaminant of interest; detecting binding of said one or more additional primary antibodies, thereby detecting additional variants of said host cell protein contaminant of interest; 20. The method of claim 18, further comprising:
20. The method of any one of claims 17 to 19, further comprising distinguishing variants of a host cell protein contaminant of interest in an antibody preparation sample by said physical parameters.
21. The method of any one of claims 17 to 20, wherein the one or more capillaries comprise a separation matrix.
22. The method of claim 21 , wherein the separation matrix comprises a carrier ampholyte.
23. The method of claim 22 , wherein the physical parameter comprises an electric charge.
24. 22. The method of claim 21, wherein the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
25. 25. The method of claim 24, wherein the physical parameter comprises molecular weight.
26. 26. The method of any one of claims 17 to 25, wherein the primary antibody is labeled with a detectable label and detecting binding of the primary antibody comprises detecting the detectable label.
27. Detecting binding of the primary antibody, contacting the primary antibody with a secondary antibody that specifically binds to the primary antibody, the secondary antibody having a detectable label; detecting the detectable label; The method according to any one of claims 17 to 26, comprising:
28. 28. The method of any one of claims 17 to 27, further comprising determining the relative or absolute amount of one or more variants of the host cell protein contaminant of interest.
29. The method of any one of claims 17 to 28, wherein the detectable label comprises a chemiluminescent label, a fluorescent label or a bioluminescent label.
30. The method of any one of claims 17 to 29, wherein the sample comprises an internal standard.
31. The method of any one of claims 17 to 30, wherein the immobilizing comprises photoimmobilizing, chemically immobilizing, or thermally immobilizing.
32. 32. The method of any one of claims 17-31, wherein the two or more mutants of host cell protein contaminants of interest comprise PLBD2, CTSD, TIMP1, acid ceramidase (ASAH1), lysosomal acid lipase (LAL), annexin, cathepsin B, anti-leukoproteinase (ALP), or fragments thereof.
Citation Information
Patent Citations
Method for analyzing sample components
JP2015516078A
Compositions and methods for detecting and quantifying host cell proteins and recombinant polypeptide products in cell lines
JP2016531304A
Methods and reagents for quantifying analytes
US20090023156A1
